Abstract
Statins are the first-line choice in Lipid-lowering therapy to reduce cardiovascular risk. In a continuous attempt to optimise treatment success, there is a need for additional research on genes and related molecular pathways that can determine the efficacy and toxicity of lipid-lowering drugs. Several variations within genes associated with lipid metabolism, including those involved in uptake, distribution and metabolism of statins have been reported. The purpose of this study was to evaluate the effect of genetic variations in the key genes responsible for statins’ metabolism and their role in personalised medicine and pharmacogenetic testing (PGx) in patients treated with such drugs. Genetic assessment for specific known SNPs within the most known genes such as ABCG2, SLCO1B1, CYP3A4, and HMGCR, appears likely to predict the efficacy of statin therapy and prevent their side effects but does not necessarily reduce the risk of cardiovascular events.
Original language | English |
---|---|
Pages (from-to) | 462-470 |
Number of pages | 9 |
Journal | Annals of Medicine |
Volume | 52 |
Issue number | 8 |
Early online date | 24 Aug 2020 |
DOIs | |
Publication status | Published - 16 Nov 2020 |
Keywords
- Statins
- hypercholesterolaemia
- personalised medicine
- HMG-COA REDUCTASE
- SLCO1B1 POLYMORPHISM
- ACUTE CORONARY SYNDROMES
- INDUCED MYOPATHY
- BCRP GENE POLYMORPHISMS
- HIGH-RISK PATIENTS
- LDL-CHOLESTEROL LEVELS
- LIPID-LOWERING RESPONSE
- CARDIOVASCULAR-DISEASE
- SINGLE NUCLEOTIDE POLYMORPHISMS